Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hart

Showing results (851-860 of 909) with videos related to

Pageof 91
Sort By:
British Journal of Clinical Pharmacology|November 16, 2020
Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part studyMarcus P J van Diemen, Ellen P Hart, Anthony Abbruscato, et al.
Molecular Cancer Therapeutics|December 8, 2011
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302Fanying Meng, James W Evans, Deepthi Bhupathi, et al.
British Journal of Clinical Pharmacology|April 22, 2021
Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patientsTim Preijers, Ri Liesner, Hendrika C A M Hazendonk, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 9, 2012
Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's diseaseJulie C Stout, Rebecca Jones, Izelle Labuschagne, et al.
Blood|March 8, 2012
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like featuresAbdel Kareem Azab, Jinsong Hu, Phong Quang, et al.
The European Respiratory Journal|March 12, 2026
Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 studyBernt Van Den Blink, Surinder S Birring, Nesrin Mogulkoc, et al.
Human Molecular Genetics|September 20, 2015
Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translationAlyssa N Coyne, Shizuka B Yamada, Bhavani Bagevalu Siddegowda, et al.
Molecular Pharmacology|April 14, 2019
Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of EvofosfamideFrancis W Hunter, Jules B L Devaux, Fanying Meng, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Female iPSC X-chromosome inactivation (XCI) erosion and its transcriptomic effects during CRISPR gene editing and neural differentiationChristina Thapa, Emily K Oh, David Sirkin, et al.
Stem Cell Reports|September 13, 2024
Scaled and efficient derivation of loss-of-function alleles in risk genes for neurodevelopmental and psychiatric disorders in human iPSCsHanwen Zhang, Ada McCarroll, Lilia Peyton, et al.
Pageof 91

Showing results (851-860 of 909) with videos related to

Sort By:
Pageof 91
British Journal of Clinical Pharmacology|November 16, 2020
Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part studyMarcus P J van Diemen, Ellen P Hart, Anthony Abbruscato, et al.
Molecular Cancer Therapeutics|December 8, 2011
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302Fanying Meng, James W Evans, Deepthi Bhupathi, et al.
British Journal of Clinical Pharmacology|April 22, 2021
Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patientsTim Preijers, Ri Liesner, Hendrika C A M Hazendonk, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 9, 2012
Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's diseaseJulie C Stout, Rebecca Jones, Izelle Labuschagne, et al.
Blood|March 8, 2012
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like featuresAbdel Kareem Azab, Jinsong Hu, Phong Quang, et al.
The European Respiratory Journal|March 12, 2026
Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 studyBernt Van Den Blink, Surinder S Birring, Nesrin Mogulkoc, et al.
Human Molecular Genetics|September 20, 2015
Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translationAlyssa N Coyne, Shizuka B Yamada, Bhavani Bagevalu Siddegowda, et al.
Molecular Pharmacology|April 14, 2019
Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of EvofosfamideFrancis W Hunter, Jules B L Devaux, Fanying Meng, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Female iPSC X-chromosome inactivation (XCI) erosion and its transcriptomic effects during CRISPR gene editing and neural differentiationChristina Thapa, Emily K Oh, David Sirkin, et al.
Stem Cell Reports|September 13, 2024
Scaled and efficient derivation of loss-of-function alleles in risk genes for neurodevelopmental and psychiatric disorders in human iPSCsHanwen Zhang, Ada McCarroll, Lilia Peyton, et al.
Pageof 91